- FDA approves Jubilant Life Sciences' quetiapine fumarate tablets
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
TORONTO — Canadian drug maker Intellipharmaceutics International is seeking approval for a generic version of a treatment for mental disorders.
Intellipharmaceutics announced Monday that it had filed an application with the Food and Drug Administration for quetiapine fumarate extended-release tablets, a generic version of AstraZeneca’s Seroquel XR.
Seroquel XR is used to treat schizophrenia, bipolar disorder and major depressive disorder. It had sales of about $823 million in 2010, according to Intellipharmaceutics. The last of the patents covering Seroquel XR expire in 2017, according to FDA records.